Endpoints

In this episode of the Endpoints, Dr. Steve Perrin, CSO at the ALS Therapy Development Institute, sits down to talk about AMX0035, a drug consisting of a combination of two small molecule compounds: sodium phenylbutyrate and tauroursodeoxycholic acid (TUDCA). Amylyx, the sponsor of AMX0035, recently completed enrollment of a 132 participant phase 2 trial.

To learn more about the ALS Therapy Development Institute and our mission to end ALS, click here.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.

In this episode of the Endpoints, Collin Hadley joins Gabrielle Bellitti, Outreach and Engagement Specialist at ALS TDI, to talk about living with ALS and using mechanical ventilation. Collin discusses how he made the decision to use mechanical ventilation, what considerations went into his decision, and what advice he has for other people with ALS who may be considering mechanical ventilation.

To access all episodes of the Endpoints Podcast, visit als.net/endpoints.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.

In this episode of the Endpoints Podcast, Dileep Dadlani, Development Director at ALS TDI is joined by Samantha Van Saun who is a Champion in ALS TDI’s ALS Community in Richmond, VA. Samantha has lost her father, uncle and sister to an aggressive form of ALS but is determined to fight back by raising awareness and funds for ALS research. Listen in to find out more about her families journey with ALS.

To access all episodes of the Endpoints Podcast, click here.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.

On this episode of the Endpoints, Dr. Steve Perrin, CEO at ALS TDI answers questions about one of the most talked about clinical trials in ALS at the moment, Brainstorm Cell Therapeutics’ NurOwn, a proposed stem-cell-based treatment. The therapy focuses on the cellular support system around a person with ALS’ motor neurons. It aims to slow disease progression by replacing the damaged system with an enhanced one.

To listen to more episodes of the Endpoints Podcast, click here.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.

In this episode of the Endpoints, Tamara Hilliard, from Fort Worth, Texas, talks about the challenges of caring for her husband, Jim, who’s living with ALS,  and his anticipated needs ahead of time. Tamara also shares her story about the pitfalls of traveling and the preparation required to succeed. Tamara and Jim have a great attitude relying on their circle of support and the great resources the community provides.

You can access all previous episodes of the Endpoints Podcast, by visiting www.als.net/endpoints.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.

In this episode of the Endpoints, Jeff Roosa, Lee, MA Chief of Police, joins Gabrielle Bellitti, Outreach and Engagement Specialist at ALS TDI, to talk about living with ALS and uniting first responders to raise money for ALS research through Arrest & Extinguish ALS. 

You can access all episodes of the Endpoints Podcast for free by visiting www.als.net/endpoints and registering.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.

In this episode, Dr. Fernando Vieira, CSO at the ALS Therapy Development Institute (ALS TDI), joins us to discuss Copper ATSM (CuATSM)clinical trials. CuATSM is a small molecule drug sponsored by the company Collaborative MedicinalDevelopment (CMD). They recently completed enrollment of a small, Phase 1 clinical trial in Australia.

You can access all episodes of the Endpoints Podcast for free by visiting www.als.net/endpoints and registering.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.

In this episode of the Endpoints, Dr. Fernando Vieira explains what we know so far about C9ORF72, a gene which has been implicated in up to 40% of cases of familial ALS. C9ORF72was discovered to be a cause of ALS 8 years ago but there is still a lot for researchers to learn about its unique characteristics. Dr. Vieira talks about some of the hurdles to overcome and what researchers are doing right now to try to address this mutation.

You can access all episodes of the Endpoints Podcast for free by visiting www.als.net/endpoints and registering.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.

In this episode, Erin Stevens, Development Manager at the ALS Therapy Development Institute (ALS TDI) chats with Andy McGovern. Andy is from Co. Leitrim in Ireland and was diagnosed with Motor Neuron Disease (MND) 41 years ago. SIGN IN TO LISTEN

In this episode of the Endpoints Podcast, Katie Bauer sits down to talk about her life as a caregiver to her husband, Charlie, as he battled ALS, while also being a mom to their young daughter, Grace.